Research Analysts Issue Forecasts for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Stock analysts at HC Wainwright decreased their FY2026 EPS estimates for Achieve Life Sciences in a report released on Monday, January 26th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of ($1.35) for the year, down from their previous forecast of ($1.30). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($0.54) EPS, FY2028 earnings at $0.47 EPS and FY2029 earnings at $1.20 EPS.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Citigroup initiated coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They issued an “outperform” rating for the company. Citizens Jmp assumed coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price target on the stock. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Achieve Life Sciences in a report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Trading Down 0.5%

Shares of ACHV stock opened at $4.34 on Wednesday. The stock has a market capitalization of $231.02 million, a price-to-earnings ratio of -3.14 and a beta of 1.71. The company’s fifty day simple moving average is $4.86 and its two-hundred day simple moving average is $3.89. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.14 and a quick ratio of 5.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences in the first quarter worth approximately $32,000. Manchester Financial Inc. grew its stake in Achieve Life Sciences by 90.8% in the 2nd quarter. Manchester Financial Inc. now owns 46,224 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 22,000 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Achieve Life Sciences in the 2nd quarter worth $263,000. Simplify Asset Management Inc. raised its position in shares of Achieve Life Sciences by 443.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock valued at $2,677,000 after buying an additional 966,667 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in shares of Achieve Life Sciences during the 2nd quarter worth $300,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.